deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01904123

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma

Sponsor: M.D. Anderson Cancer Center

Conditions Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma Recurrent Brain Neoplasm Recurrent Glioblastoma Recurrent Malignant Glioma
Interventions Laboratory Biomarker Analysis Pharmacological Study STAT3 Inhibitor WP1066
Updated 17 times since 2017 Last updated: Mar 21, 2022 Started: Jul 13, 2018 Primary completion: Mar 16, 2022 Completion: Mar 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01904123, this PHASE1 trial focuses on Metastatic Malignant Neoplasm in the Brain and Metastatic Melanoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

▶ Show 12 earlier versions

  1. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  2. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  3. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  4. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1

  5. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  6. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  7. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

  9. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

  10. May 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE1

  11. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations